10-Q · May 20, 2026
20/20 Biolabs experienced a significant revenue decline of 36.19% year-over-year in Q1 2026, with total revenue of $353,375 and a net loss of $2,174,836, a substantial drop from the loss of $764,577 in Q1 2025.…
Earnings analysis · 10-Q
AIDX earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include current-period income-statement, balance-sheet, cash-flow, or segment figures, so revenue, margins, EPS, free cash flow, and period-over-period trends cannot be assessed. The…
Read full summary
The provided 10-Q excerpt does not include current-period income-statement, balance-sheet, cash-flow, or segment figures, so revenue, margins, EPS, free cash flow, and period-over-period trends cannot be assessed. The principal disclosure is that controls remained ineffective as of June 30, 2026 because of 2 material weaknesses, with management unable to assure timely or successful remediation. The company also issued 40,798 shares in aggregate to service providers during the quarter and provided no quantitative guidance.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Remediation efforts continued
Management continued remediation during the second quarter of fiscal 2026, including formalizing control documentation, strengthening supervisory reviews, and hiring or engaging additional accounting and finance resources.
-
Service-provider equity issuances
The company issued 37,129 common shares to a service provider on April 7, 2026 and 3,669 shares to a service provider on April 27, 2026; no underwriters were involved.
-
No share repurchases
The company reported zero share repurchases during the three months ended June 30, 2026.
-
Management affirms GAAP presentation
Management stated that the consolidated financial statements fairly represent the company’s financial condition, results of operations, and cash flows as of and for the periods presented in accordance with GAAP.
What to watch
-
Ineffective disclosure controls
Disclosure controls and procedures were deemed ineffective as of June 30, 2026 because of 2 material weaknesses involving insufficient trained personnel, formal accounting controls, segregation of duties, and GAAP expertise.
-
Restatement and reporting risk
Management said it cannot assure that remediation will resolve the 2 material weaknesses in a timely manner or at all, or prevent future restatements. Failure to remediate could impair reporting accuracy and timing and could cause the common-stock market price to decline.
-
Equity dilution exposure
The company issued 37,129 shares on April 7, 2026 and 3,669 shares on April 27, 2026 to service providers, increasing the potential for equity dilution; the filing also identifies multiple outstanding warrants in Exhibits 4.2 through 4.9.
Management's outlook
The provided 10-Q excerpt contains no quantitative revenue or EPS outlook. Numeric outlook was not provided.
Earlier filings 2
10-K · March 31, 2026
20/20 Biolabs (AIDX) is an early-stage diagnostics company selling its OneTest family (primarily OneTest for Cancer) from a CLIA/CAP lab; OneTest for Cancer made ~88% of revenue in 2025. The company reported FY2025…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.